Study Links 15% BMI Drop on GLP-1 Drugs to 69% Lower Sleep Apnea Risk
Updated
Updated · ScienceAlert · May 28
Study Links 15% BMI Drop on GLP-1 Drugs to 69% Lower Sleep Apnea Risk
9 articles · Updated · ScienceAlert · May 28
89,718 U.S. patients taking GLP-1 or GLP-1/GIP drugs showed lower obesity-related disease risk when they lost more weight, with the biggest BMI reductions tied to the best outcomes.
Patients whose BMI fell at least 15% had a 69% lower risk of obstructive sleep apnea, 37% lower osteoarthritis risk and 30% lower chronic kidney disease risk than those losing 0% to 5%; heart-failure risk was 32% lower but missed statistical significance.
Patients who gained weight on treatment faced significantly higher risks of sleep apnea and heart failure than those who lost less than 5% of BMI, underscoring that the drugs' broader benefits may depend on actual weight loss.
About half stopped treatment within a year, yet were still included in the analysis, adding to concerns about whether patients can sustain weight loss and the related health gains after discontinuation.
GLP-1 drugs promise a slimmer you, but are you losing dangerous amounts of healthy muscle mass?
As new drugs offer more weight loss, is lifelong medication the only future for obesity treatment?
You've lost weight on Ozempic, but what happens to your body the moment you stop taking it?
GLP-1 Drugs in Obstructive Sleep Apnea: Mechanisms, Clinical Outcomes, and the New FDA-Approved Treatment Paradigm
Overview
GLP-1 and dual GLP-1/GIP receptor agonists, such as tirzepatide, represent a major advancement in treating obstructive sleep apnea (OSA) for adults with obesity. Since excess body fat is a key risk factor for OSA, these medications target the metabolic causes by promoting significant weight loss and improving cardiometabolic health. This leads to better sleep-disordered breathing outcomes. Tirzepatide works by activating both GLP-1 and GIP receptors, resulting in substantial weight reduction and improved OSA symptoms. The report highlights how these therapies address the root causes of OSA, offering a new and effective treatment option beyond traditional approaches.